Phase I Dose Escalation Study of Topical Bexarotene in Women at High Risk for Breast Cancer.
Journal
Cancer prevention research (Philadelphia, Pa.)
ISSN: 1940-6215
Titre abrégé: Cancer Prev Res (Phila)
Pays: United States
ID NLM: 101479409
Informations de publication
Date de publication:
04 01 2023
04 01 2023
Historique:
received:
27
05
2022
revised:
30
08
2022
accepted:
11
10
2022
pubmed:
14
10
2022
medline:
6
1
2023
entrez:
13
10
2022
Statut:
ppublish
Résumé
Bexarotene is a rexinoid that has been shown to prevent mammary tumors in mouse models but oral dosing has toxicities. This phase I study evaluates topical bexarotene, as a potential chemoprevention agent, for safety and toxicity in high-risk women for breast cancer.
Identifiants
pubmed: 36228112
pii: 709735
doi: 10.1158/1940-6207.CAPR-22-0210
pmc: PMC10391360
mid: NIHMS1844040
doi:
Substances chimiques
Bexarotene
A61RXM4375
Antineoplastic Agents
0
Banques de données
ClinicalTrials.gov
['NCT02876640']
Types de publication
Clinical Trial, Phase I
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
47-55Subventions
Organisme : NCI NIH HHS
ID : HHSN261201200034C
Pays : United States
Organisme : NCI NIH HHS
ID : N01CN35159
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA016672
Pays : United States
Informations de copyright
©2022 American Association for Cancer Research.
Références
Arch Dermatol. 2002 Mar;138(3):325-32
pubmed: 11902983
Br J Cancer. 2008 Apr 22;98(8):1380-8
pubmed: 18362934
Carcinogenesis. 2006 Jun;27(6):1232-9
pubmed: 16344269
Cell Mol Life Sci. 2010 May;67(9):1423-45
pubmed: 20140749
Cancer Lett. 2003 Nov 10;201(1):17-24
pubmed: 14580682
Cancer Prev Res (Phila). 2019 Dec;12(12):903-912
pubmed: 31484659
Arch Dermatol. 2001 May;137(5):581-93
pubmed: 11346336
J Clin Oncol. 2005 May 1;23(13):2980-7
pubmed: 15860853
Cancer Prev Res (Phila). 2009 Feb;2(2):168-74
pubmed: 19174577
Clin Cancer Res. 2014 Jul 15;20(14):3672-82
pubmed: 25028506
J Am Acad Dermatol. 2009 Oct;61(4):592.e1-9
pubmed: 19682769
Cancer Res. 2002 Nov 15;62(22):6376-80
pubmed: 12438218
Cancer Chemother Pharmacol. 2015 Dec;76(6):1235-46
pubmed: 26560487
Cancer Res. 1986 Mar;46(3):1521-5
pubmed: 3943109
Transl Oncol. 2008 Sep;1(3):148-52
pubmed: 18795149
Cancer Res. 1996 Dec 15;56(24):5566-70
pubmed: 8971154